Paolo Corradini

Research interests

Publications

• Immune effector cell–associated hematotoxicity: EHA/EBMT consensus grading and best practice recommendations

  Blood · 2023 · https://doi.org/10.1182/blood.2023020578

• Glofitamab for Relapsed or Refractory Diffuse Large B-Cell Lymphoma

  New England Journal of Medicine · 2022 · https://doi.org/10.1056/nejmoa2206913

• Long-term clinical outcomes of tisagenlecleucel in patients with relapsed or refractory aggressive B-cell lymphomas (JULIET): a multicentre, open-label, single-arm, phase 2 study

  The Lancet Oncology · 2021 · https://doi.org/10.1016/s1470-2045(21)00375-2

• COVID-19 infection in adult patients with hematological malignancies: a European Hematology Association Survey (EPICOVIDEHA)

  Journal of Hematology & Oncology · 2021 · https://doi.org/10.1186/s13045-021-01177-0

• Timing the initiation of multiple myeloma

  Nature Communications · 2020 · https://doi.org/10.1038/s41467-020-15740-9

• Clinical characteristics and risk factors associated with COVID-19 severity in patients with haematological malignancies in Italy: a retrospective, multicentre, cohort study

  The Lancet Haematology · 2020 · https://doi.org/10.1016/s2352-3026(20)30251-9

• Genomic landscape and chronological reconstruction of driver events in multiple myeloma

  Nature Communications · 2019 · https://doi.org/10.1038/s41467-019-11680-1

• Isatuximab plus pomalidomide and low-dose dexamethasone versus pomalidomide and low-dose dexamethasone in patients with relapsed and refractory multiple myeloma (ICARIA-MM): a randomised, multicentre, open-label, phase 3 study

  The Lancet · 2019 · https://doi.org/10.1016/s0140-6736(19)32556-5

• Analysis of the genomic landscape of multiple myeloma highlights novel prognostic markers and disease subgroups

  Leukemia · 2018 · https://doi.org/10.1038/s41375-018-0037-9

• Daratumumab plus bortezomib and dexamethasone versus bortezomib and dexamethasone in relapsed or refractory multiple myeloma: updated analysis of CASTOR

  Haematologica · 2018 · https://doi.org/10.3324/haematol.2018.194118

• Genomic patterns of progression in smoldering multiple myeloma

  Nature Communications · 2018 · https://doi.org/10.1038/s41467-018-05058-y

• Chemotherapy plus lenalidomide versus autologous transplantation, followed by lenalidomide plus prednisone versus lenalidomide maintenance, in patients with multiple myeloma: a randomised, multicentre, phase 3 trial

  The Lancet Oncology · 2015 · https://doi.org/10.1016/s1470-2045(15)00389-7

• Autologous Transplantation and Maintenance Therapy in Multiple Myeloma

  New England Journal of Medicine · 2014 · https://doi.org/10.1056/nejmoa1402888

• Panobinostat plus bortezomib and dexamethasone versus placebo plus bortezomib and dexamethasone in patients with relapsed or relapsed and refractory multiple myeloma: a multicentre, randomised, double-blind phase 3 trial

  The Lancet Oncology · 2014 · 10.1016/s1470-2045(14)70440-1

• ESMO Guidelines consensus conference on malignant lymphoma 2011 part 1: diffuse large B-cell lymphoma (DLBCL), follicular lymphoma (FL) and chronic lymphocytic leukemia (CLL)

  Annals of Oncology · 2012 · https://doi.org/10.1093/annonc/mds517

• Tandem Autologous/Reduced-Intensity Conditioning Allogeneic Stem-Cell Transplantation Versus Autologous Transplantation in Myeloma: Long-Term Follow-Up

  Journal of Clinical Oncology · 2011 · https://doi.org/10.1200/jco.2010.32.7312

• Bortezomib As Induction Before Autologous Transplantation, Followed by Lenalidomide As Consolidation-Maintenance in Untreated Multiple Myeloma Patients

  Journal of Clinical Oncology · 2010 · https://doi.org/10.1200/jco.2009.22.7561

• Allogeneic stem cell transplantation after reduced-intensity conditioning in patients with myelofibrosis: a prospective, multicenter study of the Chronic Leukemia Working Party of the European Group for Blood and Marrow Transplantation

  Blood · 2009 · https://doi.org/10.1182/blood-2009-07-234880

• Melphalan, Prednisone, and Lenalidomide Treatment for Newly Diagnosed Myeloma: A Report From the GIMEMA—Italian Multiple Myeloma Network

  Journal of Clinical Oncology · 2007 · https://doi.org/10.1200/jco.2007.12.3463

• Allogeneic hematopoietic stem cell transplantation for chronic myeloid leukemia in Europe 2006: transplant activity, long-term data and current results. An analysis by the Chronic Leukemia Working Party of the European Group for Blood and Marrow Transplantation (EBMT).

  PubMed · 2006

• Indications for allogeneic stem cell transplantation in chronic lymphocytic leukemia: the EBMT transplant consensus

  Leukemia · 2006 · https://doi.org/10.1038/sj.leu.2404441

• Do New Century Catalysts Unravel the Mechanism of Stereocontrol of Old Ziegler−Natta Catalysts?

  Accounts of Chemical Research · 2004 · https://doi.org/10.1021/ar030165n

• B cell lymphoma-associated chromosomal translocation involves candidate oncogene lyt-10, homologous to NF-κB p50

  Cell · 1991 · https://doi.org/10.1016/0092-8674(91)90285-7

Current projects

No projects listed.